Overview:

Summary

“Erectile Dysfunction – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global Erectile Dysfunction (ED) therapeutics market. The report identifies the key trends shaping and driving the ED market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ED therapeutics sector. GlobalData’s analysis revealed that the market grew at a CAGR of 9.8% from 2001 to 2009. The growth rate was moderate due lack of ED awareness and reluctance among male general population to discuss their sexual problem. With the patent expiry of a key product, Viagra, in 2012, the market is expected to decline after 2011, resulting in a CAGR of 4% from 2009 to 2016.

GlobalDatas analysis showed that the ED pipeline is weak. The products in the ED pipeline comprises of me-too class. Some of the promising me-too class drugs/molecules are likely to get approval in coming years which are in phase III trials. One of the promising molecule include Avanafil , which is unlikely to have much impact as market has high competition among similar products and generic erosion after 2012 due to patent expiry of Viagra (sildenafil citrate).

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global ED therapeutics market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing an overview of different phases, mechanisms of action being developed, and emerging trends. Key classes of mechanism of action include FKBP12 binder, serotonin and dopamine enhancer, PDE-5 inhibitor, and Alpha1A-adrenoreceptors antagonist.
- Analysis of the current and future market competition in the global ED therapeutics market. Key market players covered are VIVUS, Inc., and Rexahn Pharmaceuticals, Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the future market associated with ED.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global erectile dysfunction market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global erectile dysfunction market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global erectile dysfunction market landscape? – Identify, understand and capitalize.

Companies Mentioned

VIVUS, Inc
Rexahn Pharmaceuticals, Inc

1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4
2 Erectile Dysfunction: Market Characterization 5
2.1 Overview 5
2.2 Erectile Dysfunction Market Size 5
2.3 Erectile Dysfunction Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Erectile Dysfunction Market 7
2.4.1 Drivers of the Erectile Dysfunction Market 7
2.4.2 Barriers for the Erectile Dysfunction Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Erectile Dysfucntion: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profile for the Major Marketed Products in the Eerectile Dysfunction Market 11
3.3.1 Viagra (sildenafil citrate) 11
3.3.2 Cialis (tadalafil) 12
3.3.3 Levitra (verdenafil HCL) 14
3.3.4 Caverject (Alprostadil) 15
3.3.5 Muse (alprostadil) 16
3.4 Key Takeaway 18
4 Erectile Dysfucntion: Pipeline Assessment 19
4.1 Overview 19
4.2 Strategic Pipeline Assessment 19
4.2.1 Technology Trends Analytical Framework 19
4.3 Erectile Dysfunction Therapeutics – Promising Drugs under Clinical Development 20
4.4 Drugs under Clinical Development 21
4.4.1 Avanafil 21
4.4.2 Zoraxel 22
4.5 Erectile Dysfunction Therapeutics Market – Clinical Pipeline by Mechanism of Action 23
4.6 ED Pipeline – Pipeline by Clinical Phases of Development 23
4.6.1 Erectile Dysfunction Therapeutics – Phase III Clinical Pipeline 24
4.6.2 Erectile Dysfunction Therapeutics – Phase II Clinical Pipeline 24
4.6.3 Erectile Dysfunction Therapeutics – Phase I Clinical Pipeline 24
4.7 Discontinued / Suspended Drugs for Erectile Dysfunction 24
4.8 Key Takeaway 24
5 Erectile Dysfunction Market: Implications for Future Market Competition 25
6 Erectile Dysfunction Market: Future Players in the Erectile Dysfunction Market 26
6.1 Introduction 26
6.2 VIVUS, Inc. 26
6.2.1 Overview 26
6.2.2 Business Description 27
6.2.3 Sexual Dysfunction Portfolio 27
6.2.4 Erectile Dysfunction Product Portfolio 28
6.3 Rexahn Pharmaceuticals, Inc. 29
6.3.1 Overview 29
6.3.2 Sexual Dysfunction Portfolio 29
6.3.3 ED Product Portfolio 29
7 Erectile Dysfunction: Appendix 31
7.1 Definitions 31
7.2 Abbreviations 31
7.3 Research Methodology 31
7.3.1 Coverage 32
7.3.2 Secondary Research 32
7.3.3 Forecasting 33
7.3.4 Primary Research 36
7.3.5 Expert Panels 36
7.4 Contact Us 36
7.5 Disclaimer 36
7.6 Sources 37

1.1 List of Tables
Table 1: Global Erectile Dysfunction Market Revenues, 2001-2009 6
Table 2: Global Erectile Dysfunction Market Forecast, 2009-2016 7
Table 3: Major Marketed Products in the Erectile Dysfunction Market, 2010 18
Table 4: Erectile Dysfunction Therapeutics –Promising Drugs Under Clinical Development, 2010 20
Table 5: Erectile Dysfunction Therapeutics – Phase III Clinical Pipeline, 2010 24
Table 6: Erectile Dysfunction Therapeutics – Phase II Clinical Pipeline, 2010 24
Table 7: Erectile Dysfunction Therapeutics – Phase I Clinical Pipeline, 2010 24
Table 8: List of Discontinued Drugs for Erectile Dysfunction, 2010 24
Table 9: VIVUS, Inc. – Sexual Dysfunction and Erectile Dysfunction Pipeline, 2010 27
Table 10: Rexahn Pharmaceuticals Inc. – Sexual Dysfunction and Erectile Dysfunction Pipeline, 2010 29

1.2 List of Figures
Figure 1: Global Erectile Dysfunction Market Revenues, 2001–2009 6
Figure 2: Global Erectile Dysfunction Market Forecast, 2009-2016 7
Figure 3: Opportunity and Unmet Need in the Erectile Dysfunction Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Erectile Dysfunction, 2010 11
Figure 5: Technology Trends Analytic Framework of the Erectile Dysfunction Pipeline, 2010 19
Figure 6: Technology Trends Analytic Framework of Erectile Dysfunction Pipeline – Description, 2010 20
Figure 7: Erectile Dysfunction Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 23
Figure 8: Erectile Dysfunction Pipeline by Phase of Clinical Development, 2010 23
Figure 9: Implications for Future Market Competition in the Erectile Dysfunction Market, 2010 25
Figure 10: Erectile Dysfunction Therapeutics Market – Clinical Pipeline by Company, 2010 26
Figure 11: GlobalData Methodology 32
Figure 12: GlobalData Market Forecasting Model 35